医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

2018年03月09日 PM09:30
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass.

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate overview at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium on Friday, March 16, 2018 at 4:30 p.m. local time. The conference will be held March 16-17, 2018 at The InterContinental Hotel Hangzhou.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180309005084/en/

CONTACT

Investor:
Rx Communications Group
Paula Schwartz,
917-322-2216
pschwartz@rxir.com
or
Media:
SmithSolve
Alex
Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究